ACVR1 and fibrodysplasia ossificans progressiva: It is being tested in a phase 2 trial for efficacy, safety, and tolerability of INCB000928 versus placebo in patients with FOP; (ii) Garetosmab: Garetosmab is a human monoclonal antibody that binds to activin A and blocks its interaction with ACVR1.